Clinical Trial Update: Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine [Phase 4]

View source ↗

Summary

Long-term antibody persistence after a booster dose of Menitorix vaccine was studied in a Phase 4 trial; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Disease
• Neisseria Meningitidis Infection

Drugs mentioned

• Menitorix

Snippet

Sponsor: GlaxoSmithKline | Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 4 | Status: COMPLETED | Results posted: 2015-12-16